Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study

Background: Atherogenic dyslipidemia is associated with poor cardiovascular outcomes, yet markers of this condition are often ignored in clinical practice. Here, we address a clear evidence gap by assessing the prevalence and treatment of two markers of atherogenic dyslipidemia: elevated triglycerid...

Descripción completa

Detalles Bibliográficos
Autores: Halcox, Julian P., Banegas Banegas, José Ramón, Roy, Carine, Dallongeville, Jean, De Backer, Guy, Guallar, Eliseo, Perk, Joep, Hajage, David, Henriksson, Karin M., Borghi, Claudio
Tipo de recurso: artículo
Fecha de publicación:2017
País:España
Institución:Universidad Autónoma de Madrid
Repositorio:Biblos-e Archivo. Repositorio Institucional de la UAM
Idioma:inglés
OAI Identifier:oai:repositorio.uam.es:10486/680526
Acceso en línea:http://hdl.handle.net/10486/680526
https://dx.doi.org/10.1186/s12872-017-0591-5
Access Level:acceso abierto
Palabra clave:Atherogenic dyslipidemia
Cardiovascular disease
Epidemiology
Risk factors/global assessment
Medicina
id ES_4fcf7da4f85ba83f9c7415f41a741fa8
oai_identifier_str oai:repositorio.uam.es:10486/680526
network_acronym_str ES
network_name_str España
repository_id_str
spelling Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational studyHalcox, Julian P.Banegas Banegas, José RamónRoy, CarineDallongeville, JeanDe Backer, GuyGuallar, EliseoPerk, JoepHajage, DavidHenriksson, Karin M.Borghi, ClaudioAtherogenic dyslipidemiaCardiovascular diseaseEpidemiologyRisk factors/global assessmentMedicinaBackground: Atherogenic dyslipidemia is associated with poor cardiovascular outcomes, yet markers of this condition are often ignored in clinical practice. Here, we address a clear evidence gap by assessing the prevalence and treatment of two markers of atherogenic dyslipidemia: elevated triglyceride levels and low levels of highdensity lipoprotein cholesterol. Methods: This cross-sectional observational study assessed the prevalence of two atherogenic dyslipidemia markers, high triglyceride levels and low high-density lipoprotein cholesterol levels, in the study population from the European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA; N = 7641; of whom 51.6% were female and 95.6% were White/Caucasian). The EURIKA population included European patients, aged at least 50 years with at least one cardiovascular risk factor but no history of cardiovascular disease. Results: Over 20% of patients from the EURIKA population have either triglyceride or high-density lipoprotein cholesterol levels characteristic of atherogenic dyslipidemia. Furthermore, the proportions of patients with one of these markers were higher in subpopulations with type 2 diabetes mellitus or those already calculated to be at high risk of cardiovascular disease. Approximately 55% of the EURIKA population who have markers of atherogenic dyslipidemia are not receiving lipid-lowering therapy. Conclusions: A considerable proportion of patients with at least one major cardiovascular risk factor in the primary cardiovascular disease prevention setting have markers of atherogenic dyslipidemia. The majority of these patients are not receiving optimal treatment, as specified in international guidelines, and thus their risk of developing cardiovascular disease is possibly underestimatedWriting support was provided by Gary Male, PhD from Oxford Pharma Genesis, Oxford, UK and was funded by AstraZenecaBioMed Central Ltd.Departamento de Medicina Preventiva y Salud Pública y MicrobiologíaFacultad de Medicina20172017-01-01research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10486/680526https://dx.doi.org/10.1186/s12872-017-0591-5reponame:Biblos-e Archivo. Repositorio Institucional de la UAMinstname:Universidad Autónoma de MadridInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:repositorio.uam.es:10486/6805262026-06-23T12:46:27Z
dc.title.none.fl_str_mv Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study
title Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study
spellingShingle Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study
Halcox, Julian P.
Atherogenic dyslipidemia
Cardiovascular disease
Epidemiology
Risk factors/global assessment
Medicina
title_short Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study
title_full Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study
title_fullStr Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study
title_full_unstemmed Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study
title_sort Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study
dc.creator.none.fl_str_mv Halcox, Julian P.
Banegas Banegas, José Ramón
Roy, Carine
Dallongeville, Jean
De Backer, Guy
Guallar, Eliseo
Perk, Joep
Hajage, David
Henriksson, Karin M.
Borghi, Claudio
author Halcox, Julian P.
author_facet Halcox, Julian P.
Banegas Banegas, José Ramón
Roy, Carine
Dallongeville, Jean
De Backer, Guy
Guallar, Eliseo
Perk, Joep
Hajage, David
Henriksson, Karin M.
Borghi, Claudio
author_role author
author2 Banegas Banegas, José Ramón
Roy, Carine
Dallongeville, Jean
De Backer, Guy
Guallar, Eliseo
Perk, Joep
Hajage, David
Henriksson, Karin M.
Borghi, Claudio
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Departamento de Medicina Preventiva y Salud Pública y Microbiología
Facultad de Medicina
dc.subject.none.fl_str_mv Atherogenic dyslipidemia
Cardiovascular disease
Epidemiology
Risk factors/global assessment
Medicina
topic Atherogenic dyslipidemia
Cardiovascular disease
Epidemiology
Risk factors/global assessment
Medicina
description Background: Atherogenic dyslipidemia is associated with poor cardiovascular outcomes, yet markers of this condition are often ignored in clinical practice. Here, we address a clear evidence gap by assessing the prevalence and treatment of two markers of atherogenic dyslipidemia: elevated triglyceride levels and low levels of highdensity lipoprotein cholesterol. Methods: This cross-sectional observational study assessed the prevalence of two atherogenic dyslipidemia markers, high triglyceride levels and low high-density lipoprotein cholesterol levels, in the study population from the European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA; N = 7641; of whom 51.6% were female and 95.6% were White/Caucasian). The EURIKA population included European patients, aged at least 50 years with at least one cardiovascular risk factor but no history of cardiovascular disease. Results: Over 20% of patients from the EURIKA population have either triglyceride or high-density lipoprotein cholesterol levels characteristic of atherogenic dyslipidemia. Furthermore, the proportions of patients with one of these markers were higher in subpopulations with type 2 diabetes mellitus or those already calculated to be at high risk of cardiovascular disease. Approximately 55% of the EURIKA population who have markers of atherogenic dyslipidemia are not receiving lipid-lowering therapy. Conclusions: A considerable proportion of patients with at least one major cardiovascular risk factor in the primary cardiovascular disease prevention setting have markers of atherogenic dyslipidemia. The majority of these patients are not receiving optimal treatment, as specified in international guidelines, and thus their risk of developing cardiovascular disease is possibly underestimated
publishDate 2017
dc.date.none.fl_str_mv 2017
2017-01-01
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/10486/680526
https://dx.doi.org/10.1186/s12872-017-0591-5
url http://hdl.handle.net/10486/680526
https://dx.doi.org/10.1186/s12872-017-0591-5
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv BioMed Central Ltd.
publisher.none.fl_str_mv BioMed Central Ltd.
dc.source.none.fl_str_mv reponame:Biblos-e Archivo. Repositorio Institucional de la UAM
instname:Universidad Autónoma de Madrid
instname_str Universidad Autónoma de Madrid
reponame_str Biblos-e Archivo. Repositorio Institucional de la UAM
collection Biblos-e Archivo. Repositorio Institucional de la UAM
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407842473082880
score 15,301603

Similares en LA Referencia